Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis—response to comments by Ranzani et al.
Crossref DOI link: https://doi.org/10.1007/s00134-016-4548-4
Published Online: 2016-09-29
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rabilloud, Muriel
Guérin, Claude
License valid from 2016-09-29